The product of the c-erbB-2 proto-oncogene as a target for diagnosis and therapy in breast cancer

Year Immunol. 1993:7:182-92.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neoplasm* / immunology
  • Antigens, Neoplasm / analysis*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Carcinoma / diagnostic imaging*
  • Carcinoma / genetics
  • Carcinoma / pathology
  • Carcinoma, Squamous Cell / diagnostic imaging
  • Carcinoma, Squamous Cell / genetics
  • Europe
  • Female
  • Head and Neck Neoplasms / diagnostic imaging
  • Head and Neck Neoplasms / pathology
  • Humans
  • Isotope Labeling / methods
  • Lymphatic Metastasis / diagnostic imaging*
  • Mice
  • Mice, Nude
  • Neoplasm Proteins / analysis*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology
  • Neoplasm Staging / methods
  • Neoplasm Transplantation
  • Ovarian Neoplasms / diagnostic imaging
  • Ovarian Neoplasms / pathology
  • Prognosis
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / analysis*
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / immunology
  • Proto-Oncogenes*
  • Radioimmunodetection*
  • Receptor, ErbB-2
  • Technetium / pharmacokinetics
  • Tissue Distribution
  • Tumor Cells, Cultured

Substances

  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • MAS1 protein, human
  • Neoplasm Proteins
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Technetium
  • Receptor, ErbB-2